Gimsilumab

Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others. DelveInsight’s ‘Axial Spondyloarthritis (axSpA) Pipeline Insights’ report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. Some of the important takeaways from the Axial Spondyloarthritis Pipeline report: Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Axial Spondyloarthritis Emerging Therapies and Forecast The Axial Spondyloarthritis Pipeline reports lay down a thorough coverage of the ongoing clinical trials, collaborations taking place in the domain, recent happenings in the Axial Spondyloarthritis pipeline space, and growth prospects across the Axial Spondyloarthritis domain. Axial Spondyloarthritis: Overview Axial Spondyloarthritis is a chronic, inflammatory rheumatic disease that affects primarily the axial joints leading to severe pain, stiffness, and fatigue. It starts with an early inflammatory phase in which there is no structural damage in the sacroiliac joints (non-radiographic disease) progressing to later stages in which structural damage is visible on X‑ray scans of the sacroiliac joints as erosions, sclerosis, or bony bridges (radiographic disease; also known as Ankylosing Spondylitis). Discover more about the disease, treatments, and pipeline therapies @ axSpA Pipeline Assessment Axial Spondyloarthritis Pipeline Drugs Request for Sample to know more @ Axial Spondyloarthritis Pipeline Analysis, Key Companies, and Futuristic Trends Axial Spondyloarthritis Therapeutics Assessment The Axial Spondyloarthritis Pipeline report presents a kaleidoscopic view of the axSpA emerging novel therapies segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets For rich insights into merging therapies and assessment, visit Axial Spondyloarthritis Pipeline: Emerging Novel Therapies Scope of the Axial Spondyloarthritis Pipeline Report Coverage: GlobalKey Players: Izana Bioscience, UCB, Sun Pharma Global, Akeso Biopharma, Kinevant Sciences, Jiangsu Hengrui Medicine Co., Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, Mycenax Biotech, Boehringer Ingelheim, and Qyuns Therapeutics among others.Key Axial Spondyloarthritis Pipeline Therapies: Namilumab , Bimekizumab, Tofacitinib, Tildrakizumab, AK-111, NDI 031232, Gimsilumab, QX002N, SHR-0302, Jaktinib, SCB-808, FPP003, KIN-1901, ENIA11, BI 730357, and QX002N  among others. Discover more about the report offerings @ axSpA Emerging Therapies, Treatments, and Ongoing Clinical Trials Table of Contents Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions Related Reports Axial Spondyloarthritis MarketDelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030" report. Non-Radiographic Axial Spondyloarthritis MarketDelveInsight's "Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2030" report. Spondylolisthesis Market InsightsDelveInsight's “Spondylolisthesis Market Insights, Epidemiology, and Market Forecast-2030" report. Ankylosing Spondylitis MarketDelveInsight’s ‘Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast–2030’ report. Global Kinase Inhibitor In Autoimmune Diseases MarketDelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030’ report. Adenosine Deaminase Severe Combined Immunodeficiency MarketDelveInsight's "Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology, and Market Forecast-2030" report. Adult-Onset Still Disease MarketDelveInsight’s “Adult-onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2030” report. Browse through our posts ABSSSI Pipeline Analysis Parkinson's Disease Risk FactorsWearable Healthcare Devices Market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

As the world and biopharma grapple with developing vaccines and drugs against COVID-19, researchers are turning to a handful of drugs that show particular promise. Several of those drugs are by companies with offices or headquarters in the San Francisco Bay Area. Here’s a look. As the world and biopharma grapple with developing vaccines and drugs against COVID-19, the disease caused by the novel coronavirus, researchers are turning to a handful of drugs that show particular promise . Several of those drugs are by companies with offices or headquarters in the San Francisco Bay Area. Here’s a look. Genentech’s Actemra . Actema (tocilizumab) is approved for use for rheumatoid arthritis (RA). It was developed by Roche’s Chugai Pharmaceutical unit and is marketed in the U.S. by Genentech, based in South San Francisco. In addition to being used for RA, it can be utilized to suppress cytokine release syndrome in CAR-T cancer patients. Cytokine release syndrome, a massive hyper-reaction of the immune system, is also found in patients toward the end of COVID-19. Roche is launching a Phase III trial of Actemra plus standard-of-care patients with COVID-19 pneumonia. After treatment, patients in the trial will be followed for 60 days and an interim analysis will be performed in hopes of early evidence of efficacy. It expects to begin enrolling patients in April. Gilead Sciences’ remdesivir . The Foster City-based Gilead is running multiple clinical trials of its remdesivir in Seattle, Everett, Washington, Hong Kong, Singapore, Taiwan and South Korea. Remdesivir is a nucleotide analog with broad-spectrum antiviral activity in in vitro studies and in in vivo studies in animals against Ebola, Marburg, MERS and SARS. MERS and SARS are both caused by coronaviruses that have at least some similarities to the coronavirus causing COVID-19. It should be emphasized how unusually fast the launch of these trials is, which underlines the urgency of the coronavirus eipdemic. Gilead initially announced it was considering remdesivir for COVID-19 in late January. It was originally developed to treat Ebola but has shown some success in targeting coronaviruses. Genentech’s Tamiflu . The company’s Tamiflu (oseltamivir), which was developed by Gilead Sciences and is marketed by Genentech, is part of a COVID-19 clinical trial being held at Rajavithi University in Bangkok, Thailand. The trial will combine protease inhibitors, Tamiflu and favipiravir with chloroquine, a drug most commonly used to treat malaria. Quite a bit of attention is being focused on chloroquine as a treatment for COVID-19. In addition to malaria, the drug is used to treat lupus and rheumatoid arthritis. Favipiravir is an influenza drug marketed by a subsidiary of FujiFilm, which has shown encouraging results in Chinese clinical trials in 340 COVID-19 patients. Amgen’s Mvasi, the Generic Version of Genentech’s Avastin. Avastin (bevacizumab) is a recombinant humanized monoclonal antibody, an anti-VEGF drug. It is approved to treat several forms of cancer, including colorectal, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, ovarian cancer and recurrent glioblastoma. The generic version is being tested in at least one clinical trial in China against COVID-19 pneumonia. It’s important to note that these are just Bay Area biopharma companies. Numerous other companies are testing drugs as possible treatments for COVID-19, including Roivant’s Gimsilumab,AbbVie’s Kaletra, Regeneron, Nascent Biotech, Johnson & Johnson, and many others working to develop vaccines against the virus, including Moderna, Sanofi, CureVac and many others. An industry-wide conference call demonstrated how the biopharma industry is working together as “one team,” said Pfizer’s chief scientific officer Mikael Dolsten.